Dueling JAMA articles judge whether ACOs have been successful

In response to the view of two Duke University professors who claimed accountable care organizations (ACOs) “have failed to produce needed efficiencies,” another JAMA Viewpoints article defends the ACO model and encourages CMS not to abandon it.

The response comes from Zirui Song, MD, PhD, of Massachusetts General Hospital, and Elliott Fisher, MD, MPH, director of the Dartmouth Institute for Health Policy and Clinical Practice. They argue there is limited evidence on the effects on ACO contracts, and what evidence exists suggests the model can lead to modest savings. What could be more compelling, Song and Fisher write, is the benefits to quality achieved through ACOs.

“This evidence provides grounds for cautious optimism,” their article states. “That quality is improving substantially could be consistent with the notion that even weak incentives can change behavior when they are aligned with core professional values.”

Rather than end ACO experiments and focus on telemedicine and wearable devices, as Duke University professors Kevin Schulman, MD, and Barak Richman, JD, PhD, advocated, Song and Fisher argue there are broader problems with value-based care that need to be addressed. The challenges they identify include incentives too weak to encourage physicians to assume more risk, hospitals’ reluctance to “right-size” their industry and perhaps wishful thinking from doctors and hospitals that fee-for-service payment will remain the norm.

For more on how Song and Fisher propose to tackle these challenges, click on the link below:

 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.